S&P 500

5.127,79

1,26%

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Tenax Therapeutics Inc (TENX)
Tenax Therapeutics Inc (TENX) Notícias

TENX

Tenax Therapeutics (TENX)

Tenax Therapeutics Inc

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:TENX

1 2 3 4 5 6 7 8 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
30/04/2024	08:30	GlobeNewswire Inc.	Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)	NASDAQ:TENX	Tenax Therapeutics Inc
09/04/2024	09:30	GlobeNewswire Inc.	Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”	NASDAQ:TENX	Tenax Therapeutics Inc
28/03/2024	09:30	GlobeNewswire Inc.	Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results	NASDAQ:TENX	Tenax Therapeutics Inc
12/03/2024	09:30	GlobeNewswire Inc.	Tenax Therapeutics to Present at the 36th Annual Roth Conference	NASDAQ:TENX	Tenax Therapeutics Inc
29/02/2024	11:00	GlobeNewswire Inc.	Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024	NASDAQ:TENX	Tenax Therapeutics Inc
26/02/2024	18:31	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:TENX	Tenax Therapeutics Inc
23/02/2024	18:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:TENX	Tenax Therapeutics Inc
20/02/2024	18:01	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:TENX	Tenax Therapeutics Inc
20/02/2024	10:30	GlobeNewswire Inc.	Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan	NASDAQ:TENX	Tenax Therapeutics Inc
14/02/2024	16:58	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:TENX	Tenax Therapeutics Inc
09/02/2024	19:00	Edgar (US Regulatory)	Form 424B4 - Prospectus [Rule 424(b)(4)]	NASDAQ:TENX	Tenax Therapeutics Inc
08/02/2024	10:16	GlobeNewswire Inc.	Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering	NASDAQ:TENX	Tenax Therapeutics Inc
08/02/2024	02:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:TENX	Tenax Therapeutics Inc
07/02/2024	22:01	GlobeNewswire Inc.	Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)	NASDAQ:TENX	Tenax Therapeutics Inc
06/02/2024	10:30	GlobeNewswire Inc.	Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)	NASDAQ:TENX	Tenax Therapeutics Inc
02/02/2024	19:24	Edgar (US Regulatory)	Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]	NASDAQ:TENX	Tenax Therapeutics Inc
12/01/2024	19:46	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:TENX	Tenax Therapeutics Inc
01/12/2023	18:47	Edgar (US Regulatory)	Form S-1 - General form for registration of securities under the Securities Act of 1933	NASDAQ:TENX	Tenax Therapeutics Inc
17/11/2023	10:30	GlobeNewswire Inc.	Tenax Therapeutics Announces Professor Javed Butler, M.D., M.P.H, M.B.A., joins PH-HFpEF Scientific Advisory Board	NASDAQ:TENX	Tenax Therapeutics Inc
13/11/2023	18:31	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:TENX	Tenax Therapeutics Inc
13/11/2023	10:30	GlobeNewswire Inc.	Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), Initiation of Phase 3 sites expected 2023	NASDAQ:TENX	Tenax Therapeutics Inc
27/10/2023	09:15	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:TENX	Tenax Therapeutics Inc
27/10/2023	09:13	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:TENX	Tenax Therapeutics Inc
16/10/2023	17:18	Edgar (US Regulatory)	Form PRE 14A - Other preliminary proxy statements	NASDAQ:TENX	Tenax Therapeutics Inc
19/07/2023	09:30	GlobeNewswire Inc.	Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)	NASDAQ:TENX	Tenax Therapeutics Inc
31/05/2023	17:11	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:TENX	Tenax Therapeutics Inc
28/04/2023	09:37	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	NASDAQ:TENX	Tenax Therapeutics Inc
28/04/2023	09:31	Edgar (US Regulatory)	Proxy Statement (definitive) (def 14a)	NASDAQ:TENX	Tenax Therapeutics Inc
14/04/2023	17:16	Edgar (US Regulatory)	Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)	NASDAQ:TENX	Tenax Therapeutics Inc
13/04/2023	18:01	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)	NASDAQ:TENX	Tenax Therapeutics Inc